Back

Elevated risk of cardiovascular disease in patients with schizophrenia: a systematic review and meta-analysis

29 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Mental health and cardiovascular vulnerability Psychiatric Disorders and Heart Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Gustavo Adrian Medina Avalos

Tijuana (Mexico)

7 More presentations in this session

Presentation thumbnail
An increased risk of major ischaemic events among autistic people
Mr O. Al Rubaie (Cambridge, GB)
Abstract Slides Video
Presentation thumbnail
The hidden patient in heart failure: psychological distress and gender-based differences in caregiver quality of life: a cross-sectional study
Assistant Professor J. Murillo-Cruz (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Chronic stress biology and psychosocial profiles in inherited cardiovascular conditions: hair cortisol, endocannabinoids, and interoception
Doctor V. Varela (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Real-World observations on levels of demoralization, dignity-related distress and resilience in patients with heart failure
Doctor F. Ferranti (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Prevalence of ANOCA and discordance between anginal symptoms and coronary functional abnormalities in patients with mental health disorders: Insights from the Japanese CMD Registry
Doctor K. Nakamura (Kumamoto, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Mental health and cardiovascular vulnerability

The Event

Event poster

ESC Congress 2026

29 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Systematic review and meta-analysis of increased ischemic heart disease vulnerability in schizophrenia patients
25 August 2023
thumbnail
Congress Presentation
Cardiovascular risk factors and outcomes in patients with thymoma receiving cancer therapy
21 June 2025
thumbnail
Congress Presentation
Sex-specific drug-target Mendelian randomisation on the effects of lipid-modifying targets on cardiovascular disease
4 April 2025
thumbnail
Congress Presentation
SCORE2 underestimates the risk of cardiovascular disease among people with depression and anxiety disorder
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources